Regeneron Pharmaceuticals, Inc. Declares Quarterly Dividend of $0.88 (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a quarterly dividend on Tuesday, February 4th,RTT News reports. Shareholders of record on Thursday, February 20th will be given a dividend of 0.88 per share by the biopharmaceutical company on Thursday, March 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%.

Regeneron Pharmaceuticals Stock Down 0.9 %

NASDAQ:REGN opened at $666.85 on Tuesday. Regeneron Pharmaceuticals has a 52 week low of $663.43 and a 52 week high of $1,211.20. The stock’s fifty day moving average is $720.81 and its two-hundred day moving average is $921.72. The stock has a market capitalization of $73.28 billion, a price-to-earnings ratio of 16.50, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Analyst Ratings Changes

A number of brokerages recently commented on REGN. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Bank of America reiterated an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Royal Bank of Canada dropped their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Finally, Evercore ISI decreased their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,004.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.